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Administration of supplemental oxygen is the first-line therapy for hypoxemic patients. Supplemental oxygen therapy is one of the most commonly used medical interventions, and is indicated when hypoxemia is suspected by history or physical examination or is documented by laboratory data. Oxygen may be delivered using low- or high-flow devices. Low-flow devices, such as a nasal oxygen catheter, nasal cannula, or simple oxygen mask, deliver varying levels of inspiratory fraction of oxygen (F~IO2~), depending on the patient's breathing pattern, peak inspiratory flow rate, tidal volume, and inspiratory time. Conventional high-flow devices, such as a Venturi mask or air-entrainment nebulizer, provide a more constant F~IO2~ than the low-flow devices, through steady entrainment of room air using the Bernoulli effect. However, at high patient inspiratory flow rates, entrained room air dilutes the oxygen and lowers F~IO2~.

A high-flow nasal cannula (HFNC) is a relatively new high-flow device being used for adults with hypoxemia. This system provides much higher and more predictable gas flow rates and F~IO2~ than conventional high-flow devices. The apparatus consists of an air/oxygen blender, an active heated humidifier, a single heated circuit, and a nasal cannula. At the air/oxygen blender, F~IO2~ is set from 0.21 to 1.0 in a flow of up to 60 L/min. These higher flow rates match the patients' inspiratory flow rates, may reduce anatomical dead space, and increase carbon dioxide (CO~2~) washout and create a positive end-expiratory pressure (PEEP) effect \[[@b1-kjim-31-1-36],[@b2-kjim-31-1-36]\]. The gas is heated and humidified with the active humidifier and delivered through the heated circuit. HFNC is more comfortable than continuous positive airway pressure and noninvasive positive pressure ventilation (NIV).

HFNC was first used and has been studied most extensively for neonatal and pediatric patients. Recently, its use for critically ill adult patients has been increasing dramatically. However, the current literature on the use of HFNC for adults includes heterogeneous patient populations and clinical diagnoses, and has yielded inconsistent reports. Previous studies have drawn attention to how HFNC can benefit adults, due to its ability to deliver a desired F~IO2~. Potential mechanisms of clinical benefits during HFNC use are as follows \[[@b3-kjim-31-1-36]\]: (1) the small, loose-fitting nasal prongs enhance comfort \[[@b4-kjim-31-1-36]-[@b6-kjim-31-1-36]\]; (2) the heat and humidification facilitate secretion removal and prevent desiccation and epithelial injury by increasing the water content of mucus \[[@b7-kjim-31-1-36],[@b8-kjim-31-1-36]\], and reduce the work of breathing by decreasing the metabolic cost of breathing \[[@b1-kjim-31-1-36],[@b9-kjim-31-1-36]\]; (3) the high nasal flow rate reduces inspiratory entrainment of room air and deliver more reliable F~IO2~ \[[@b10-kjim-31-1-36]-[@b12-kjim-31-1-36]\]; (4) the washout of the upper airway dead space improves the efficiency of ventilation \[[@b13-kjim-31-1-36]-[@b15-kjim-31-1-36]\] and enhances oxygen delivery; and (5) the PEEP counterbalances auto-PEEP and decreases the work of breathing \[[@b11-kjim-31-1-36],[@b16-kjim-31-1-36]-[@b21-kjim-31-1-36]\]. Studies have increasingly focused on the potential clinical applications and benefits of HFNC, which include enhanced oxygenation in hypoxemic respiratory failure due to pneumonia \[[@b5-kjim-31-1-36],[@b15-kjim-31-1-36]\] and cardiogenic pulmonary edema \[[@b22-kjim-31-1-36]\], and decreased respiratory rates in idiopathic pulmonary fibrosis patients \[[@b16-kjim-31-1-36]\]. Postoperatively, HFNC can improve thoracoabdominal synchrony in cardiothoracic and vascular surgery patients \[[@b23-kjim-31-1-36]\], and increase end-expiratory lung volume \[[@b24-kjim-31-1-36]\] and lower escalation of therapy \[[@b25-kjim-31-1-36]\] in patients with cardiac surgery. It can also improve oxygenation and respiratory mechanics in do-not-intubate patients \[[@b26-kjim-31-1-36]\]. However, most studies addressing these applications have been of low quality with anecdotal case reports, case series, and some preliminary controlled trials, limiting the ability to draw conclusions or make recommendations. Frat et al. \[[@b27-kjim-31-1-36]\] recently reported encouraging results of a randomized multicenter trial in which HFNC significantly improved 90-day mortality versus standard oxygen and NIV in an acute hypoxemic respiratory failure, but further physiological and randomized controlled studies are needed to confirm the precise clinical advantages of HFNC.

In this issue of *Korean Journal of Internal Medicine*, Yoo et al. \[[@b28-kjim-31-1-36]\] reported a single-center study of a historic retrospective cohort analysis that was designed to assess the clinical efficacy of HFNC compared with NIV in patients with post-extubation respiratory failure (PERF). Among the 73 PERF patients with hypoxemia and/or hypercapnia, 39 patients were managed with NIV and 34 with HFNC. Avoidance of reintubation, duration of Intensive Care Unit (ICU) and hospital stay, ICU and hospital mortality, and incidence of ICU-acquired pneumonia associated with PERF were compared between the two strategies. The results revealed that the reintubation avoidance rate did not differ between the NIV and HFNC groups (66.7% and 79.4%, *p* = 0.223). The length of hospital stay, ICU-acquired pneumonia-associated PERF, and ICU and hospital mortalities were also similar (*p* \> 0.05). Subgroup analyses of patients with hypercapnia, avoidance of reintubation, and ICU and hospital mortalities also revealed no significant differences (*p* \> 0.05).

Reintubation due to PERF is associated with increased duration of ICU and hospital stay and mortality \[[@b29-kjim-31-1-36],[@b30-kjim-31-1-36]\]. Patients recently extubated are prone to oxygen desaturation and frequently require high-flow oxygen therapy, and HFNC can be useful for these patients. According to previous studies about the clinical effects of HFNC in post-extubation patients, HFNC demonstrated similar effects to a high-flow face mask \[[@b6-kjim-31-1-36]\], and resulted in better oxygenation and comfort, fewer desaturation and interface displacements, and a lower reintubation rate than a Venturi mask \[[@b31-kjim-31-1-36]\]. Although a retrospective analysis, the study \[[@b28-kjim-31-1-36]\] in this issue may be the first to have directly compared HFNC with NIV in PERF patients. In other studies, escalation to NIV was used as an important clinical parameter of failure of high-flow devices, not a comparator.

The study by Yoo et al. \[[@b28-kjim-31-1-36]\] presents an important issue to be considered: can HFNC substitute for NIV in PERF patients? The results of similar effectiveness between HFNC and NIV suggest the possibility that HFNC can substitute for NIV in these patients. PERF is a comprehensive entity that encompasses hypoxemic and hypercapnic respiratory failure. In patients with acute hypoxemic respiratory failure, HFNC has been found to be effective \[[@b32-kjim-31-1-36]\] and superior to NIV in the prevention of intubation in patients with PaO~2~/F~IO2~ ≤ 200 mmHg and 90-day mortality \[[@b27-kjim-31-1-36]\]. However, for hypercapnic respiratory failure, NIV has been established as a primary modality. Evidence for a role of HFNC in hypercapnic respiratory therapy is limited and controversial \[[@b33-kjim-31-1-36],[@b34-kjim-31-1-36]\]. In managing PERF with NIV, because of poor mask tolerance, NIV is frequently inapplicable in some patients \[[@b35-kjim-31-1-36],[@b36-kjim-31-1-36]\]. This problem frequently interferes with clinicians' active use of NIV and clinicians seek other measures that can substitute for NIV. However, the practical difficulties in NIV application cannot justify the substitution of NIV by HFNC or skipping NIV prior to intubation in PERF patients. The possibility for substitution of NIV by HFNC should be carefully evaluated with appropriate measures. Because of its retrospective design and small study size, Yoo et al. \[[@b28-kjim-31-1-36]\] could not obtain sound results on this issue. The clinical practice of NIV cannot be controlled appropriately, and application of NIV should be considered before reintubation of failed patients with HFNC. These factors could have been responsible for the finding that NIV was ineffective even in hypercapnic PERF patients. Appropriate randomized trials are needed to address the possibility of substituting NIV with HFNC: before appropriate evidence is available, substitution of NIV by HFNC or skipping NIV application before reintubation cannot be justified.

HFNC has several advantages over conventional oxygen delivery systems, resulting in better physiological effects. Under the expectation of potential clinical effects, it has been applied in a variety of patients with diverse underlying diseases. However, concrete clinical evidence is still very limited. The clinical benefits of HFNC in specific populations, long-term effects, and optimal use of HFNC in relation to other modalities should be confirmed through future clinical studies.
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